Last 16 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | 0.63 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.49 | — | 7.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 0.68 | 0.37 | 1.41 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 50.0% | — | — | — | — | — | — | — | — | 100.0% | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | -782.2% | — | — | — | — | — | — | — | — | -199733.3% | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | -4511.3% | — | — | — | — | — | — | — | — | -223100.0% | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -487.2% | -7.0% | -9.7% | -8.2% | -4.0% | 2.8% | 1.2% | -0.8% | 2.9% | -2.7% |
| — | — | — | — | — | — | — | -12118.5% | -347.5% | -885.9% | -885.9% | -235.7% | +203.5% | — | — | — | — | |
| ROA | -536.6% | 193.5% | -391.7% | 43.1% | -100.7% | -32.8% | -161.3% | -74.7% | -6.6% | -8.7% | -7.3% | -3.9% | 2.7% | 1.2% | -0.8% | 2.7% | -2.5% |
| — | +689.6% | -142.9% | +157.6% | -1434.4% | -278.6% | -2107.3% | -1839.8% | -343.5% | -852.9% | -851.2% | -243.3% | +209.2% | — | — | — | — | |
| ROIC | -203.3% | — | -24.9% | — | — | — | — | -41.0% | -4.4% | -5.6% | -5.2% | -2.7% | -0.4% | -0.3% | -0.7% | -0.4% | — |
| — | — | — | — | — | — | — | -1423.0% | -898.2% | -1528.5% | -684.9% | -604.7% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | 0.01 | — | 7.70 | — | — | — | — | — | 0.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | — | 0.05 | — | 0.02 | 0.02 | 0.04 | 0.05 | 0.27 | 0.01 | 0.08 | 0.02 | 0.41 | 0.63 | 0.96 | 1.34 | 3.56 | 11.65 |
| — | +26.5% | — | -90.8% | +102.4% | -48.8% | +106.0% | -35.6% | -98.1% | -91.3% | -98.2% | -88.4% | -94.6% | — | — | — | — | |
| Quick Ratio | — | 0.05 | — | 0.02 | 0.02 | 0.04 | 0.05 | 0.27 | 0.01 | 0.08 | 0.02 | 0.41 | 0.63 | 0.96 | 1.34 | 3.56 | 11.65 |
| — | +26.5% | — | -90.8% | +102.4% | -48.8% | +106.0% | -35.6% | -98.1% | -91.3% | -98.2% | -88.4% | -94.6% | — | — | — | — | |
| Interest Coverage | -15.24 | 31.16 | 2.58 | 14.98 | -23.87 | -4.03 | -75.71 | -156.24 | -125.60 | -243.76 | -10.27 | -9.52 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 16 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NKGN stock.
NKGen Biotech, Inc. Common Stock's current P/E is -0.0x. The average P/E over the last 1 quarters is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NKGen Biotech, Inc. Common Stock's business trajectory between earnings reports.